EASD 2025 15 - 19 September 2025

Semaglutide and risk reduction of major adverse limb events in diabetes: A pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials

Authors :

Subodh Verma¹; Marc P. Bonaca²; Joakim Nordanstig³; John B. Buse⁴; Matthew A. Cavender⁴; Kenneth W. Mahaffey⁵; Richard Pratley⁶; Peter Rossing⁷; Alex Videmark⁸; Andrei-Mircea Catarig⁸; Søren Rasmussen⁸; Florian M. M. Baeres⁸; Mads D. M. Engelmann⁸; Darren K. McGuire⁹

Affiliations

View Details Hide Details

Keywords

Diabetes

Congress oral presentation

GLP-1 RA

Semaglutide

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

Semaglutide and risk reduction of major adverse limb events in diabetes: A pooled analysis of 13,975 participants from the SOUL, FLOW and STRIDE randomised trials